Summary

The 7 major LAG 3 next generation immunotherapy markets reached a value of US$ 370.1 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 4,403.0 Million by 2034, exhibiting a growth rate (CAGR) of 25.25% during 2024-2034.

The LAG 3 next generation immunotherapy market has been comprehensively analyzed in IMARC’s new report titled “LAG 3 Next Generation Immunotherapy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034”. Lymphocyte-activation gene 3 (LAG 3) is an immune checkpoint receptor protein that is found on the cell surface of effector T cells and regulatory T cells (Tregs) and controls T cell response, activation, and growth. It belongs to the immunoglobulin superfamily (IgSF) and associates with the CD3/T-cell receptor (TCR) complex. LAG 3 (lymphocyte activation gene-3) next generation immunotherapy refers to the use of LAG 3-targeting therapies, such as monoclonal antibodies, as a new approach to treating cancer and autoimmune diseases. These therapies work by blocking the interaction between LAG 3 and its ligand, MHC class II, which is expressed on the surface of antigen-presenting cells. This prevents the inhibition of T cell activation and function, thereby enhancing the immune response against cancer cells or autoimmune-associated cells. LAG 3 (lymphocyte activation gene-3) next generation immunotherapy harnesses the power of the immune system to fight cancer and autoimmune diseases and has the potential to be less toxic and more effective than traditional treatments.

The rising incidences of cancer and the increasing demand for advanced cancer therapeutics are primarily driving the global LAG 3 next generation immunotherapy market. In addition to this, the emerging popularity of LAG 3 next generation immunotherapy, since it specifically targets cancer cells while leaving healthy cells unharmed, is also creating a positive outlook for the market. Moreover, the shifting preferences of doctors and patients from chemotherapy and radiation therapy towards LAG 3 next generation immunotherapy on account of its numerous associated benefits, such as fewer side effects and longer-lasting responses, is further bolstering the market growth. Besides this, the introduction of favorable guidelines by several regulatory bodies across the globe to support faster approvals of pipeline drugs and clinical trials that encourage the entry of new products is also acting as a significant growth-inducing factor. Additionally, the inflating government and private investments in R&D activities in the field of cancer immunotherapy are further propelling the global market. Apart from this, the widespread adoption of LAG 3 next generation immunotherapy as a monotherapy or in combination with other immunotherapies, such as checkpoint inhibitors, for the treatment of various types of cancer, including melanoma, lung cancer, and head and neck cancer, is expected to drive the global LAG 3 next generation immunotherapy market in the coming years.

IMARC Group’s new report provides an exhaustive analysis of the LAG 3 next generation immunotherapy market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for LAG 3 next generation immunotherapy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the LAG 3 next generation immunotherapy market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the LAG 3 next generation immunotherapy market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the LAG 3 next generation immunotherapy market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current LAG 3 next generation immunotherapy marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug overview
Mechanism of action
Regulatory status
Clinical trial results
Drug uptake and market performance

Late-Stage Pipeline Drugs

Drug overview
Mechanism of action
Regulatory status
Clinical trial results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the LAG 3 next generation immunotherapy market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the LAG 3 next generation immunotherapy market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the LAG 3 next generation immunotherapy market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of cases (​2018-2034​) going for LAG 3 next generation immunotherapy across the seven major markets?
What is the number of cases (​2018-2034​) going for LAG 3 next generation immunotherapy by age across the seven major markets?
What is the number of cases (​2018-2034​) going for LAG 3 next generation immunotherapy by gender across the seven major markets?
What is the number of cases (​2018-2034​) going for LAG 3 next generation immunotherapy by type across the seven major markets?
What is the size of the LAG 3 next generation immunotherapy patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of LAG 3 next generation immunotherapy?
What will be the growth rate of patients across the seven major markets?

LAG 3 Next Generation Immunotherapy: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for LAG 3 next generation immunotherapy drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the LAG 3 next generation immunotherapy market?
What are the key regulatory events related to the LAG 3 next generation immunotherapy market?
What is the structure of clinical trial landscape by status related to the LAG 3 next generation immunotherapy market?
What is the structure of clinical trial landscape by phase related to the LAG 3 next generation immunotherapy market?
What is the structure of clinical trial landscape by route of administration related to the LAG 3 next generation immunotherapy market?

ページTOPに戻る

Table of Contents

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 LAG 3 Next Generation Immunotherapy - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence

5 LAG 3 Next Generation Immunotherapy - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 LAG 3 Next Generation Immunotherapy - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (​2018-2034​)
7.2.4 Epidemiology by Gender (​2018-2034​)
7.2.5 Epidemiology by Type (​2018-2034​)
7.2.6 Diagnosed Cases (​2018-2034​)
7.2.7 Patient Pool/Treated Cases (​2018-2034​)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (​2018-2034​)
7.3.4 Epidemiology by Gender (​2018-2034​)
7.3.5 Epidemiology by Type (​2018-2034​)
7.3.6 Diagnosed Cases (​2018-2034​)
7.3.7 Patient Pool/Treated Cases (​2018-2034​)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (​2018-2034​)
7.4.4 Epidemiology by Gender (​2018-2034​)
7.4.5 Epidemiology by Type (​2018-2034​)
7.4.6 Diagnosed Cases (​2018-2034​)
7.4.7 Patient Pool/Treated Cases (​2018-2034​)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (​2018-2034​)
7.5.4 Epidemiology by Gender (​2018-2034​)
7.5.5 Epidemiology by Type (​2018-2034​)
7.5.6 Diagnosed Cases (​2018-2034​)
7.5.7 Patient Pool/Treated Cases (​2018-2034​)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (​2018-2034​)
7.6.4 Epidemiology by Gender (​2018-2034​)
7.6.5 Epidemiology by Type (​2018-2034​)
7.6.6 Diagnosed Cases (​2018-2034​)
7.6.7 Patient Pool/Treated Cases (​2018-2034​)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (​2018-2034​)
7.7.4 Epidemiology by Gender (​2018-2034​)
7.7.5 Epidemiology by Type (​2018-2034​)
7.7.6 Diagnosed Cases (​2018-2034​)
7.7.7 Patient Pool/Treated Cases (​2018-2034​)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (​2018-2034​)
7.8.4 Epidemiology by Gender (​2018-2034​)
7.8.5 Epidemiology by Type (​2018-2034​)
7.8.6 Diagnosed Cases (​2018-2034​)
7.8.7 Patient Pool/Treated Cases (​2018-2034​)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (​2018-2034​)
7.9.4 Epidemiology by Gender (​2018-2034​)
7.9.5 Epidemiology by Type (​2018-2034​)
7.9.6 Diagnosed Cases (​2018-2034​)
7.9.7 Patient Pool/Treated Cases (​2018-2034​)

8 LAG 3 Next Generation Immunotherapy - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 LAG 3 Next Generation Immunotherapy - Unmet Needs

10 LAG 3 Next Generation Immunotherapy - Key Endpoints of Treatment

11 LAG 3 Next Generation Immunotherapy - Marketed Products
11.1 List of LAG 3 Next Generation Immunotherapy Marketed Drugs Across the Top 7 Markets
11.1.1 Nivolumab/Relatlimab - Bristol-Myers Squibb
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Clinical Trial Results
11.1.1.4 Safety and Efficacy
11.1.1.5 Regulatory Status

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 LAG 3 Next Generation Immunotherapy - Pipeline Drugs
12.1 List of LAG 3 Next Generation Immunotherapy Pipeline Drugs Across the Top 7 Markets
12.1.1 RAPA-201 - Rapa Therapeutics LLC
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Nivolumab - Bristol-Myers Squibb
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. LAG 3 Next Generation Immunotherapy - Attribute Analysis of Key Marketed and Pipeline Drugs

14. LAG 3 Next Generation Immunotherapy – Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events

15 LAG 3 Next Generation Immunotherapy - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 LAG 3 Next Generation Immunotherapy - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 LAG 3 Next Generation Immunotherapy - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 LAG 3 Next Generation Immunotherapy - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 LAG 3 Next Generation Immunotherapy - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 LAG 3 Next Generation Immunotherapy - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 LAG 3 Next Generation Immunotherapy - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 LAG 3 Next Generation Immunotherapy - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 LAG 3 Next Generation Immunotherapy - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 LAG 3 Next Generation Immunotherapy - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 LAG 3 Next Generation Immunotherapy - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 LAG 3 Next Generation Immunotherapy - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 LAG 3 Next Generation Immunotherapy - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 LAG 3 Next Generation Immunotherapy - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 LAG 3 Next Generation Immunotherapy - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 LAG 3 Next Generation Immunotherapy - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 LAG 3 Next Generation Immunotherapy - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 LAG 3 Next Generation Immunotherapy - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 LAG 3 Next Generation Immunotherapy - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 LAG 3 Next Generation Immunotherapy - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 LAG 3 Next Generation Immunotherapy - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 LAG 3 Next Generation Immunotherapy - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 LAG 3 Next Generation Immunotherapy - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 LAG 3 Next Generation Immunotherapy - Access and Reimbursement Overview

16 LAG 3 Next Generation Immunotherapy - Recent Events and Inputs From Key Opinion Leaders

17 LAG 3 Next Generation Immunotherapy Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats

18 LAG 3 Next Generation Immunotherapy Market – Strategic Recommendations

19 Appendix